$KRRO

Cerio Jeffrey sold $72K of KRRO

Cerio Jeffrey (General Counsel) sold 6,609 shares of Korro Bio, Inc. (KRRO) at $10.83 on 2026-06-16.

Original reporting
SEC EDGAR · Cerio Jeffrey
Published Jun 17, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:29 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$KRRO
Neutral
medium confidence
Mentioned
$KRRO
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KRRONeutralLow
01

Why it matters

The newest fact is the reported open-market sale by the company’s General Counsel, including share count, price, and post-transaction holdings.

02

Market read

Traders may monitor insider activity, but this filing alone does not change the company’s outlook.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-scheduled personal liquidity needs; without additional disclosures, the signal is weak.

Relevance 3/10Novelty 3/10Timing: filed 2026-06-17, transaction dated 2026-06-16

Background

The article is a SEC Form 4 insider transaction for Korro Bio, Inc. (KRRO).

Company-level read

Ticker impact

$KRRONeutralMedium confidence
Context

Korro Bio insider Cerio Jeffrey, General Counsel, sold 6,609 shares at $10.83 on 2026-06-16 via an open-market sale Form 4.

Expected impact

Likely limited near-term impact; traders may view it as mild negative sentiment but not a catalyst.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the filing lacks any accompanying corporate event, guidance, or operational update.

Market effects

No clear sector read-through from a single insider sale at a small biotech.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan could be interpreted by some traders as more discretionary selling, but the article provides no reason or context for the sale.

Key entities

  • Korro Bio, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Cerio Jeffrey

    General Counsel who sold 6,609 shares.

Related articles

$KRROMed

Korro Bio, Inc. (KRRO): Results of Operations and Financial Condition

Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 4 krro-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update — KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical tria